Charter Research Investment Group buys $2,238,772 stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Charter Research Investment Group scooped up 205 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 19,744 shares of Celgene Corporation which is valued at $2,238,772.Celgene Corporation makes up approximately 2.51% of Charter Research Investment Group’s portfolio.

Other Hedge Funds, Including , Vsr Financial Services boosted its stake in CELG in the latest quarter, The investment management firm added 1,323 additional shares and now holds a total of 7,350 shares of Celgene Corporation which is valued at $833,417. Celgene Corporation makes up approx 0.13% of Vsr Financial Services’s portfolio.Los Angeles Capital Management Equity Research Inc reduced its stake in CELG by selling 19,635 shares or 25.46% in the most recent quarter. The Hedge Fund company now holds 57,491 shares of CELG which is valued at $6,543,051. Celgene Corporation makes up approx 0.05% of Los Angeles Capital Management Equity Research Inc’s portfolio.Coconut Grove Bank boosted its stake in CELG in the latest quarter, The investment management firm added 20 additional shares and now holds a total of 704 shares of Celgene Corporation which is valued at $81,333. Celgene Corporation makes up approx 0.07% of Coconut Grove Bank’s portfolio.First Dallas Securities reduced its stake in CELG by selling 100 shares or 1.31% in the most recent quarter. The Hedge Fund company now holds 7,532 shares of CELG which is valued at $814,285. Celgene Corporation makes up approx 0.60% of First Dallas Securities’s portfolio.

Celgene Corporation closed down -0.84 points or -0.77% at $107.95 with 26,07,239 shares getting traded on Monday. Post opening the session at $109.08, the shares hit an intraday low of $107.6801 and an intraday high of $109.44 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *